Background - Cancer immunotherapy has revolutionized melanoma treatment, but the high number of non-responders still emphasizes the need for improvement of therapy. One potential avenue for enhancing anti-tumor treatment is through the modulation of coagulation and platelet activity. Both have been found to play an important role in the tumor microenvironment, tumor growth and metastasis. Preclinical studies indicate a beneficial effect, clinical data has been inconsistent. - Methods - We examined a cohort of advanced, non-resectable melanoma patients (n = 2419) derived from the German prospective multicenter skin cancer registry ADOReg, who were treated with immune checkpoint inhibitors (ICI). The patients were classified based on whether it was documented that they received platelet aggregation inhibition (PAI) (n = 137) (acetylsalicylic acid (ASA) or clopidogrel), anticoagulation (AC) (n = 185) (direct oral anticoagulation (DOAC), phenprocoumon, heparins) at the start of ICI or no antithrombotic medication (n = 2097) at any point during ICI treatment. The study endpoints were best overall response (BOR), progression-free survival (PFS) and overall survival (OS). - Results - A significantly improved PFS was observed in patients documented to receive ASA (15.1 vs 6.4 months, HR 0.67, 95 % CI: 0.5 to 0.88, p = 0.0047) as well as in patients to receive AC (15.1 vs. 6.4 months, HR 0.7, 95 % CI: 0.53 to 0.91, p = 0.01) compared to patients for whom no antithrombotic medication was documented. Multivariate analysis of OS showed significant risk reduction in patients who received DOAC (HR 0.68, 95 % CI: 0.49 to 0.92, p = 0.0170) or phenprocoumon (HR: 0.44, 95 % CI: 0.19 to 0.85, p = 0.0301). - Conclusion - Our study indicates a positive prognostic effect of anticoagulant and antiplatelet concomitant medication in melanoma patients receiving ICI. Further studies are needed to confrim the cancer-related benefit of adding anticoagulation or platelet inhibition to ICI treatment.
European journal of cancer Amsterdam [u.a.] : Elsevier, 1992 214(2025) vom: Jan., Artikel-ID 115159, Seite 1-11
von Martin Benedikt ; Eckard Böde ; Andreas Bossert ; Jens Braband ; Tino Brade ; Niklas Braun ; Tobias Braun ; Simon Burton ; Thomas Dallmann ; Werner Damm ; Tobias Düser ; Lukas Elster ; Tim Fingscheidt ; Marco Fistler ; Marzena Franek ; Martin Fränzle ; Jonas Freyer ; Roland Galbas ; Roman Gansch ; Dirk Geyer ; Lukas Haas ; Arsalan Haider ; Peter Heidl ; Matthias Hein ; Andreas Heyl ; Johannes Hiller ; Hardi Hungar ; Dieter Hutter ; Rolf Jung ; Cornel Klein ; Jörg Krüger ; Thomas Kuhn ; Jacob Langner ; Markus Maurer ; Kerstin Mayr ; André Meyer-Vitali ; Eike Möhlmann ; Adam Molin ; Björn Möller ; Jürgen Niehaus ; Bastian Nolte ; Marcus Nolte ; Stefan Otten ; Jan Peleska ; Steven Peters ; Tim Poguntke ; Florian Poprawa ; Jan Reich ; Philipp Rosenberger ; Nayel Fabian Salem ; Bernhard Schick ; Daniel Schneider ; Stefan-Alexander Schneider ; Christian Schyr ; Carsten Thomas ; Mario Trapp ; Florence Wagner ; Nicolas Wagener ; Timo Woopen ; Thomas Zeh
von Sophie Gottschalk ; Hans-Helmut König ; Tina Mallon ; Josefine Schulze ; Jan Weber ; Silke Böttcher ; Uta Sekanina ; Thomas Asendorf ; Eva Hummers ; Michael H. Freitag ; Nils Schneider ; Tim Friede ; Friedemann Nauck ; Martin Scherer ; Gabriella Marx ; Judith Dams
von Tom G. Bailey ; Timo Klein ; Annelise Lins Meneses ; Kayla B. Stefanidis ; Stefanie Lina Rüdiger ; Daniel John Green ; Tim Stuckenschneider ; Stefan Schneider ; Christopher D. Askew
von Hannah Weigert ; Tim Stuckenschneider ; Lena Pickert ; Andrea Rossi ; Anna Meyer ; Gereon Nelles ; Ralf-Joachim Schulz ; Wilhelm Stahl ; Stefan Schneider ; M. Christina Polidori
